Altamira Therapeutics Files May 2025 6-K Report
Ticker: CYTOF · Form: 6-K · Filed: May 9, 2025 · CIK: 1601936
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Altamira Therapeutics (formerly Auris Medical) filed its May 6-K, confirming its reporting status.
AI Summary
Altamira Therapeutics Ltd. (formerly Auris Medical Holding Ltd.) filed a Form 6-K on May 9, 2025, reporting as a foreign private issuer. The company, incorporated in Bermuda with its principal executive office in Hamilton, is in the Pharmaceutical Preparations industry. This filing is for the month of May 2025 and requires the company to file annual reports under Form 20-F.
Why It Matters
This filing indicates ongoing reporting requirements for Altamira Therapeutics as a foreign private issuer, providing updates to the SEC and investors.
Risk Assessment
Risk Level: low — This is a routine reporting form for a foreign private issuer and does not contain specific financial or operational news.
Key Players & Entities
- Altamira Therapeutics Ltd. (company) — Filer
- Auris Medical Holding Ltd. (company) — Former company name
- May 9, 2025 (date) — Filing date
- 001-36582 (other) — SEC File Number
FAQ
What is the primary purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public in its home country, files or makes public with a stock exchange, or distributes or makes public to its security holders.
What was Altamira Therapeutics Ltd. formerly known as?
Altamira Therapeutics Ltd. was formerly known as Auris Medical Holding Ltd.
On what date was this Form 6-K filed?
This Form 6-K was filed on May 9, 2025.
Which form is Altamira Therapeutics required to file annual reports under?
Altamira Therapeutics is required to file annual reports under Form 20-F.
Where is Altamira Therapeutics Ltd.'s principal executive office located?
Altamira Therapeutics Ltd.'s principal executive office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 9, 2025 regarding Altamira Therapeutics Ltd. (CYTOF).